Back to Results
First PageMeta Content
Alcohols / Morphinans / Drug rehabilitation / Ketones / Dosage forms / Buprenorphine / Naloxone / Opioid dependence / Drug Addiction Treatment Act / Chemistry / Organic chemistry / Pharmacology


Initial REMS Approval: December[removed]NDA[removed]SUBOXONE (buprenorphine and naloxone) sublingual tablet CIII
Add to Reading List

Open Document

File Size: 454,99 KB

Share Result on Facebook

City

Reference / Richmond / /

Company

Assessments Reckitt Benckiser Pharmaceuticals Inc. / Reckitt Benckiser Pharmaceuticals Inc. / /

Country

United States / /

Event

Product Issues / Product Recall / FDA Phase / Person Communication and Meetings / /

Facility

I store SUBOXONE / Store SUBOXONE / Midlothian Turnpike / /

IndustryTerm

retail pharmacies / healthcare professionals / heavy machinery / /

MedicalCondition

loss of consciousness / drug addiction / Allergic reaction / fewer withdrawal symptoms / Headache / hives / hallucinations / coma / nausea / drowsiness / serious withdrawal symptoms / diarrhea / normal / runny nose / Constipation / infections / cramps / wheezing / head injury / insomnia / hypothyroidism / vomiting / pain / Drug withdrawal syndrome / muscle aches / dizziness / withdrawal symptoms / rash / /

MedicalTreatment

counseling / behavioral therapy / /

Organization

FDA / National Technical Information Service / /

/

Position

Pharmacist / Physician / Introductory Pharmacist / /

Product

A. Medication / symptoms / signs / Put / Sublingual Tablet / mannitol / naloxone / SUBOXONE / Opioid / Drug / Medication Guide / SUBOXONE Tablet / CIII ® Buprenorphine / REMS / /

ProvinceOrState

Virginia / /

PublishedMedium

the Medication Guide / /

SocialTag